The evidence regarding the association of OS and response assessment by RECIST 1.1, iRECIST, and mRECIST in HCC treated with PD-1 inhibitor is scarce, especially in real-world settings. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.